CHRU de Brest
Brest, 29609, France
NCT Number: NCT03469102
Tumors are characterized by a great heterogeneity. Characterizing this intra-tumor heterogeneity is a major challenge in oncology to improve the therapeutic management and move towards personalized medicine adapted to each patient. However, intra-tumor heterogeneity remains rarely used for diagnostic purposes The discovery of an adrenal mass can occur in different circumstances. Detection of an adrenal mass can be done in a context of secreting syndrome, in the assessment of an extra-adrenal neoplasia or fortuitously when performing an imaging for another reason. The etiologies are numerous (cortical tumors, medullary tumors, metastatic lesion of a extra-adrenal neoplasia, others). The adrenal masses can be divided into two categories, depending on whether they are hyperfunctional or not. In patients without an oncological history, an adrenal mass discovered is most often a benign adenoma, but requires an endocrine assessment. In patients with known primary cancer, approximately 30% of the adrenal masses are malignant.
In all cases, the diagnostic procedure includes an imaging assessment to characterize the lesion and an endocrine assessment. CT scan performed without and after intravenous iodinated contrast agent injection is the first-line examination to assess an adrenal mass.
18F-FDG-PET may be indicated as second-line for characterizing an adrenal mass. Adrenal tumor SUVmax (Standard Uptake Value) and adrenal tumor SUVmax / liver SUVmax ratio are routinely used to determine the malignancy of a lesion. Although very useful for assessing the glucose metabolism of a given lesion, these parameters do not allow assessing the heterogeneity of tumor uptake. The texture analysis corresponds to an analysis of the spatial distribution of FDG uptake, and allows, by the calculation of many indices, an evaluation of the heterogeneity of the tumors.
The hypothesis of our study is that the texture parameters could have an additional diagnostic value to improve the performance of conventional quantitative parameters to determine the malignancy of a lesion.
The objective of this study is to investigate the diagnostic value of texture indices in a large cohort of patients presenting an adrenal lesion
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Brest, 29609, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 6 months
Area Under the Curve
Time frame: 6 months
For each cut off value : Sensibility(%)
Time frame: 6 months
For each cut off value : Specificity(%)
Time frame: 6 months
For each cut off value : Positive and Negative Predictive Value (%),
Time frame: 6 months
For each cut off value : Accuracy (%)
University Hospital, Brest
Other
Diagnostic Value of 18FDG PET/CT Textural Indices in Patients With an Adrenal Lesion
Acronym: ImpactTexture
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06330558
Adrenal Gland Diseases, Adrenal Gland Neoplasms
View Trial DetailsNCT04804163
Adenocarcinoma, Adrenal Gland Diseases
Qingdao, Shandong, China
View Trial DetailsNCT04570176
Adenocarcinoma, Adrenal Gland Diseases
Qingdao, Shandong, China
View Trial DetailsNCT03830593
ACTH Syndrome, Ectopic, Adrenal Adenoma
Samsun, Turkey (Türkiye)
View Trial Details